A recent study in the International Journal of Drug Policy, citing data from the 2023 International Cannabis Policy Study, found that 6% of […]
A recent survey from Faces & Voices of Recovery, a national leader in the drug policy field, found that Americans’ beliefs about addiction […]
A recent study in the International Journal of Drug Policy, citing data from the 2023 International Cannabis Policy Study, found that 6%
A recent survey from Faces & Voices of Recovery, a national leader in the drug policy field, found that Americans’ beliefs about addiction […]
The Trump administration’s recent attempts to loosen the nation’s laws regarding marijuana and psychedelics mark a significant departure from the positions favored […]
This post is reprinted with permission from Sue’s Substack, by Sue Rusche. Both complaints say that all four companies market and […]
The Trump administration’s recent attempts to loosen the nation’s laws regarding marijuana and psychedelics mark a significant departure from the positions favored […]
This data compounds a series of studies undermining claims that marijuana is medicine.
This post is reprinted with permission from Sue’s Substack, by Sue Rusche. Both complaints say that all four companies market and […]
The wider administration has taken steps to profoundly normalize the drug and open the door to significant further commercialization.
First it was Mehmet Oz, the guru of pseudoscience, who began giving an FDA-unapproved drug—CBD—to Medicare patients.
Despite the industry--and now the federal government--claiming that marijuana has therapeutic benefits, evidence continues to emerge showing that the drug reduces health.
Kevin Sabet's recent Washington Post op-ed, co-authored with Charles Fain Lehman, generated a lot of interest--and some pushback.
April 29 was National Fentanyl Awareness Day, a day dedicated to raising awareness about the life-threatening risks of fentanyl.